Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta‐analysis
Authors:
- 5 December 2007
- journal article
- review article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 15 (2) , 89-102
Abstract
Summary. To assess the effects of prophylactic lamivudine on reactivation and mortality following immunosuppressive therapy in hepatitis B surface antigen (HBsAg)‐positive patients, we performed a meta‐analysis. Systematic review and meta‐analysis of randomized and nonrandomized prospective controlled trials and retrospective comparative case series were identified through The Cochrane Hepato‐Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and LILACS. The primary outcomes were virological reactivation, clinical reactivation and mortality. Secondary outcomes included hepatitis B virus (HBV)‐related mortality, liver histology, discontinuation or disruption of immunosuppressive therapy, lamivudine‐resistant HBV strains and adverse events. A total of 21 studies were included, two of which were randomized controlled trials. Clinical and virological reactivation were significantly reduced in the lamivudine group [odds ratio (OR) 0.09; 95% confidence interval (CI) 0.05–0.15 and OR 0.04; 95% CI 0.01–0.14 respectively]. All‐cause mortality was significantly reduced in the lamivudine group (OR 0.36; 95% CI 0.23–0.56) which translates to only 11 patients who need to be treated to prevent one death. Lamivudine significantly reduced HBV‐related mortality, and discontinuations or disruptions of the immunosuppressive treatment. No adverse effects of lamivudine were recorded, and resistance to lamivudine occurred in low rates. We demonstrated a clear benefit of lamivudine in terms of clinical and virological HBV reactivation, overall mortality, HBV‐related mortality and interruptions or discontinuations in the immunosuppressive treatment. Lamivudine should be administered prophylactically to HBsAg‐positive patients who are about to receive immunosuppressive therapy.Keywords
This publication has 66 references indexed in Scilit:
- Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patientsBreast Cancer Research and Treatment, 2004
- Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxisGut, 2004
- Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal follow-upSupportive Care in Cancer, 2004
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximabAmerican Journal of Hematology, 2001
- A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphomaBone Marrow Transplantation, 2001
- Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivationBritish Journal of Haematology, 2000
- Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important roleJournal of Medical Virology, 2000
- LamivudineDrugs, 1999
- Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitroHepatology, 1995